Dyne Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 2, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 2, 2026
DYN$17.92-3.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| Year Ended December 31, | |||
|---|---|---|---|
| (in thousands, except share and per share data) | 2025 | 2024 | 2023 |
| Operating expenses: | |||
| Research and development | $398,333 | $281,406 | $210,762 |
| General and administrative | 69,851 | 62,480 | 31,400 |
| Total operating expenses | 468,184 | 343,886 | 242,162 |
| Loss from operations | (468,184) | (343,886) | (242,162) |
| Other (expense) income: | |||
| Interest income | 29,859 | 26,922 | 7,641 |
| Interest expense | (6,192) | — | — |
| Other expense, net | (1,697) | (454) | (1,416) |
| Total other income, net | 21,970 | 26,468 | 6,225 |
| Net loss | $(446,214) | $(317,418) | $(235,937) |
| Net loss per share, basic and diluted | $(3.47) | $(3.37) | $(3.95) |
| Weighted average common shares outstanding, basic and diluted | 128,442,723 | 94,143,565 | 59,683,851 |
| Comprehensive loss: | |||
| Net loss | $(446,214) | $(317,418) | $(235,937) |
| Other comprehensive loss: | |||
| Unrealized gains on marketable securities, net | 469 | 6 | 571 |
| Comprehensive loss | $(445,745) | $(317,412) | $(235,366) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.